SBC Medical Group Holdings Inc (SBC) FY2024 10-K Annual Report
SBC Medical Group Holdings Inc (SBC) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Mar 28, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
SBC Medical Group Holdings Inc FY2024 10-K Analysis
Business Overview
- • Core business: Medical aesthetics franchising, procurement, management, and rental services focusing on clinic networks in Japan
- • New emphasis on franchising revenue model change in 2024: fixed royalty fees per clinic replacing percentage of sales, authorized MCs to use patents/trademarks
- • Strategic shift: Discontinued clinic operation staff support services and plan merger of subsidiaries (Shobikai Sub into Lange Sub) to streamline operations
- • Quantitative highlight: Franchising revenue up 44.96% to $61.0M; net income increased 21.08% to $46.7M despite JPY depreciation impact of $16.0M on revenues
- • Noteworthy fact: Recorded $15.1M impairment loss on intangible asset and $13.0M stock-based compensation expense related to warrants issued in 2022 upon business combination completion
Management Discussion & Analysis
- • No revenue or profit figures disclosed; focus on internal control weaknesses and remediation efforts
- • Identified material weaknesses in internal controls including control environment, activities, risk assessment, communication, monitoring
- • Post-business combination internal controls inadequate, requiring significant management resources for remediation through end of 2025
- • Added accounting personnel, established related party policy, improved segregation of duties, started external SOX compliance consultants engagement
- • No cash flow, capital allocation, segment, or forward-looking financial guidance provided in this section
Risk Factors
- • Regulatory risk from Japanese Medical Care Act limiting voting control over Medical Corporations despite equity interests
- • Geopolitical exposure in Japan with all 241 treatment centers operated under six related-party Medical Corporations
- • Operational risk from reliance on franchisor-franchisee contracts and service contracts with Medical Corporations for clinic management
- • Competitive threat from expanding "Shonan Beauty Clinic" brand in Japan, Vietnam, and the US cosmetic medical services market
- • Financial risk due to significant drop in operating cash flow from $50.7M in 2023 to $20.6M in 2024 despite revenue growth
SBC Medical Group Holdings Inc FY2024 Key Financial MetricsXBRL
Revenue
$205M
▲ +6.1% YoY
Net Income
$47M
▲ +13619.5% YoY
Gross Margin
76.0%
▲ +503bp YoY
Operating Margin
34.2%
▲ +3514bp YoY
Net Margin
22.7%
▲ +2252bp YoY
ROE
23.9%
▲ +2956bp YoY
Total Assets
$266M
▲ +1152.4% YoY
EPS (Diluted)
$0.48
▲ +14.3% YoY
Operating Cash Flow
$21M
▲ +1065.0% YoY
Source: XBRL data from SBC Medical Group Holdings Inc FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on SBC Medical Group Holdings Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.